Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, announced it has launched Palonosetron Hydrochloride Injection, USP in the United States as a therapeutic generic equivalent for Aloxi® as approved by the U.S. Food and Drug Administration. Palonosetron Hydrochloride Injection, USP is indicated as an antiemetic.
Brainomix, a pioneer in artificial intelligence (AI) imaging solutions, has announced it has entered into a partnership with German pharmaceutical company Boehringer Ingelheim for a collaborative programme of activity to improve the care of patients with fibrosing lung disease in the US.
Nirrin Technologies, a developer of analytical tools poised to transform bioprocess analysis, announce the launch of their Atlas™ system for at-line excipient and product titer quantitation in downstream bioprocessing applications.
BioArctic AB's partner Eisai announced that Leqembi® generic name: lecanemab has been launched in China. Leqembi received approval in January 2024 as a treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementia. China is the third country to launch Leqembi following the United States and Japan.
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, announced it has launched Tranexamic Acid Injection, USP in the United States as a therapeutic generic equivalent for Cyklokapron® as approved by the U.S. Food and Drug Administration.